When it is available, will we take it? Public perception of hypothetical COVID-19 vaccine in Nigeria

Author:

Adebisi Yusuff AdebayoORCID,Alaran Aishat Jumoke,Bolarinwa Obasanjo AfolabiORCID,Akande-Sholabi WuraolaORCID,Lucero-Prisno Don EliseoORCID

Abstract

AbstractCOVID-19 pandemic is a global public health threat facing mankind. There is no specific antiviral treatment for COVID-19, and no vaccine is currently available. This study aims to understand the perception of the public towards hypothetical COVID-19 vaccine in Nigeria. We conducted a cross-sectional survey in August 2020 across the 36 states of Nigeria using an online questionnaire. The questionnaire includes sections on the demographic characteristics of the respondents and their perception regarding hypothetical COVID-19 vaccine. A total of 517 respondents completed and returned the informed consent along with the questionnaire electronically. Data were coded and abstracted into the Microsoft Excel spreadsheet and loaded into the STATA 14 software for final analysis. The results showed that more than half of the respondents were male 294 (56.87%). Most of the respondents (385, 74.47%) intend to take the COVID-19 vaccine when it becomes available. Among the 132 respondents that would not take the COVID-19 vaccine, the major reason for non-acceptance is unreliability of the clinical trials 49 (37.12%), followed by the belief that their immune system is sufficient to combat the virus 36 (27.27%). There are significant association with the respondents age and having reservations toward vaccination [χ2= 19.0389 P-value=0.00] and COVID-19 vaccine acceptance [χ2=24.3316 P-value=0.00]. Furthermore, geographical location and acceptance of the COVID-19 vaccine [χ2=13.7786 P-value=0.02] are significantly associated. Even though the majority of our respondents are willing to take the COVID-19 vaccine, our findings reiterate the need to reassure the public that any vaccine which becomes available is safe and effective.

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3